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ABSTRACT
Although more than 90% systemic mastocytosis (SM) patients express gain 
of function mutations in the KIT receptor, recent next generation sequencing has 
revealed the presence of several additional genetic and epigenetic mutations in a 
subset of these patients, which confer poor prognosis and inferior overall survival. 
A clear understanding of how genetic and epigenetic mutations cooperate in 
regulating the tremendous heterogeneity observed in these patients will be essential 
for designing effective treatment strategies for this complex disease. In this review, 
we describe the clinical heterogeneity observed in patients with mastocytosis, the 
nature of relatively novel mutations identified in these patients, therapeutic strategies 
to target molecules downstream from activating KIT receptor and finally we speculate 
on potential novel strategies to interfere with the function of not only the oncogenic 
KIT receptor but also epigenetic mutations seen in these patients.
INTRODUCTION
Based on World Health Organization (WHO) 
current classification, Myeloproliferative disorders, also 
known as myeloproliferative neoplasms (MPNs), are 
grouped into the following seven diseases: (1) Chronic 
Myelogeneous Leukemia (CML), (2) Chronic Neutrophilic 
Leukemia (CNL), (3) Polycythemia Vera (PV), (4) Primary 
Myelofibrosis (PM), (5) Essential Thrombocythemia 
(ET), (6) Chronic Eosinophilic Leukemia (CEL) and (7) 
Mastocytosis [1]. These diseases present with a wide 
range of symptoms. While some of these MPNs progress 
slowly; others develop into aggressive diseases such as 
Acute Myeloid Leukemia (AML). Although significant 
progress has been made in treating some forms of MPNs; 
Mastocytosis still poses significant challenges. Greater 
than 90% patients with mastocytosis possess somatic 
gain-of-function mutations in the KIT receptor tyrosine 
kinase, primarily an aspartic acid to valine substitution 
(D816V) in the second catalytic domain, which results in 
enhanced survival and cell autonomous growth of neoplastic 
mast cells (MC). Neoplastic mast cells accumulate in different 
organs, leading to a highly heterogeneous disease, which 
affects both children and adults. Furthermore, approximately 
10–15% oncogenic Kit mutations are also observed in core-
binding factor leukemias (CBF-AML) [2–4]. Managing 
clinical manifestations associated with KIT mutations in 
mastocytosis has posed significant impediment in large part 
due to resistance against currently described therapies. In this 
review, we discuss the challenges and strategies to effectively 
diagnose, treat, and manage mastocytosis associated with 
oncogenic KIT and other newly identified mutations in genes 
encoding epigenetic regulators and spliceosome machinery.
KIT receptor and mastocytosis
Mast cells (MCs) and their committed progenitors 
express the KIT receptor (CD117), a Type III receptor 
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tyrosine kinase that is expressed in hematopoietic stem and 
progenitor cells, germ cells, melanocytes, and interstitial 
cells of Cajal [5]. The KIT receptor is encoded by a 21-
exon containing gene located on human chromosome 4q12, 
which expresses a 976 amino acid protein with a molecular 
weight of 145 kDa [6, 7]. The receptor is composed of an 
extracellular domain (ECD), juxtamembrane domain (JMD), 
and a tyrosine-kinase domain (TKD). The TKD contains a 
phosphotransferase domain (PTD) and an ATP binding site. 
The ligand for KIT receptor, Stem cell factor (SCF) or KIT 
ligand, induces the development, proliferation, maturation, 
survival and mediator release from MCs [8]. Under normal 
physiological conditions, MCs are tightly regulated by the 
availability of KIT ligand SCF, however under conditions 
when a gain-of-function receptor is present; uncontrolled 
proliferation, enhanced survival and cell autonomous 
growth of MCs can contribute to the disease pathogenesis 
[9]. The term mastocytosis is attributed to a group of rare 
heterogeneous disorders that are characterized by abnormal 
infiltration of neoplastic MCs into one or more organs 
[10]. Based on its clinical presentation, mastocytosis can 
be classified into two major forms, cutaneous (CM) and 
systemic (SM) [1, 10–12]. Mastocytosis affects both children 
and adults and is mostly acquired, although rare familial 
cases have been reported [10, 13]. In children, the disease is 
primarily restricted to the skin and mostly regresses during 
adolescence. In contrast, in adults the disease can be chronic 
and systemic in nature. In the pediatric population, the 
disease predominantly appears in the form of various skin 
lesions that reveals atypical MC infiltration and aggregates, 
and is termed as CM. In adults, the disease is chronic and 
systemic, invariably affecting the bone marrow (BM) and 
is termed SM [14]. The adult SM patients may manifest the 
indolent form of the disease or may present with a more 
aggressive form or even progress to developing leukemic 
variants of SM with abnormal accumulation of mast cells in 
various tissues; primarily skin, bone marrow, and visceral 
organs leading to multi-organ failure and shortened life span 
[1, 15]. Most adult patients are diagnosed with the indolent 
form of SM (ISM) where skin is the predominant organ 
affected, while the aggressive forms of SM (ASM, MC 
leukemia) are relatively rare in occurrence [10, 13, 16–18]. 
What is difficult to reconcile is the fact that how a single 
mutation in the KIT receptor can potentially contribute 
to such disease heterogeneity. In an effort to explain 
these observations, recent studies have begun to focus on 
identifying other non-KIT associated mutations that may 
contribute to the disease heterogeneity in these patients.
Prevalence of different KIT mutations in 
different forms of mastocytosis
In 2008, mastocytosis was diagnosed and classified 
according to WHO into seven different categories: 
Cutaneous Mastocytosis (CM), indolent SM (ISM), 
smoldering SM (SSM), SM with non-associated hematologic 
non-mast cell disease (SM-AHNMD), aggressive SM 
(ASM), mast cell leukemia (MCL), MC sarcoma (MCS) 
and extracutaneous mastocytoma [1, 10, 12, 13, 19–23]. 
For some of these categories, particularly CM, ISM, SM-
AHNMD, ASM and MCL, subvariants have been identified 
based on observed clinical and biological features (Table 1). 
WHO guidelines define the diagnosis of SM based on either: 
the fulfillment of one major criterion along with 1 minor 
criterion; or fulfillment of at least 3 minor criteria [20, 23]. 
The major criterion involves multifocal infiltration of MCs 
(MC burden) in BM or major other organs as determined 
by tryptase staining. Minor criteria include: (1) presence of 
atypical MCs in tissues, (2) presence of activating gain-of-
function point mutation in KIT D816V in neoplastic MCs 
in the peripheral blood, BM or visceral organs, (3) aberrant 
expression of CD2 and/or CD25 in neoplastic MCs, and 
(4) persistent elevated serum tryptase level (> 20 ng/ml).
In adults the presence of KIT D816V mutation is 
found in > 80% of cases, while in children, KIT mutations are 
found in > 75% of skin biopsies, however only 25% of these 
are D816V mutations [24–27]. KIT mutations in children are 
primarily localized to the extracellular domain (ECD) and 
the most frequent mutation reported is a deletion at position 
419. The question whether pediatric mastocytosis is a clonal 
disease also continues to be debated [28, 29]. In general, 
majority of pediatric patients lack the presence of D816V 
mutation (only 25–36%) [24, 25], although a significant 
number of these patients carry additional forms of activating 
KIT mutations (D835Y, D816I, del417–418, D419Y, C443Y, 
S476I, ITD502–503, K509I, D572A) [24, 25]. Overall 75% 
of pediatric patients have some alternations in KIT, laying 
support to the now prevailing hypothesis that childhood 
mastocytosis is a clonal disease, although the spectrum of the 
disease and mutations are narrower than those seen in adults 
[24]. Importantly, in cases of pediatric familial mastocytosis, 
no KIT D816V mutations have been reported, instead other 
mutations (K509I, A533D, N822I, S849I, del419, del559–
560) and rare germline mutations are observed [30–32] 
(Table 2). In addition to the spectrum of mutations described 
above, single nucleotide polymorphisms (SNPs) have also 
been found in KIT, such as (M541L, K546K, I798I, N828N 
and L862L) [33]. Although the M541L sequence variation 
seems to confer increased sensitivity to SCF, the clinical 
significance of this SNP is still unclear.
The presence of activating mutations in adult patients 
is mostly restricted to the PTD of the KIT receptor [34]. In 
ISM patients, the presence of KIT D816V is virtually 100%, 
when detected using sensitive assays on purified BM MCs 
[35, 36]. A small percentage of ISM cases do progress to an 
aggressive phenotype, which appears to be determined by 
the presence of KIT D816V mutation in the non-mast cell 
compartment acting as a predictor of aggressiveness of the 
disease. ISM comprises of 2 subsets: well-differentiated SM 
and SSM (smoldering SM) [11, 13, 23]. Well-differentiated 
SM is characterized by either non-D816V KIT or absence 
of KIT mutation. However, SSM is a special subvariant of 
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SM that presents with high mast cell burden, high serum 
tryptase levels, organomegaly without organ failure but has a 
clinical course that is stable over many years- hence the name 
“smoldering”. Some of SSM patients eventually progress to 
advanced forms of SM (ASM, SM-AHNMD, MCL), while 
others remain in the smoldering stage. In SSM, the KIT 
D816V mutation is usually found in the neoplastic MCs, as 
well as in the non-MC lineage cells [13, 37].
While the prognosis of pediatric CM, ISM and 
SSM is usually good, in ASM, the prognosis is relatively 
poor with a median survival of only 41 months [38]. 
ASM presents itself with progressive evolution leading to 
impaired BM function, hepatic and splenic failure, fractures 
and severe weight loss. ASM patients present themselves 
primarily with KIT D816V mutation in neoplastic MCs, 
although other KIT mutations (D820G, V559I) have also 
been reported [39, 40] (Table 2). While KIT mutations are 
clearly involved in ASM and its progression to MCL, recent 
studies demonstrate the presence of additional mutations 
in these patients, which may help explain the aggressive 
nature of ASM, progression to MCL and perhaps resistance 
to tyrosine kinase inhibitors (TKIs) [41–44].
SM-AHNMD occurs between 5–20% of all SM cases 
and is considered a special subtype of advanced SM. 
SM-AHNMD is the second most common form of SM 
and usually occurs in combination with ‘associated clonal 
hematological non-mast cell lineage disease’ (AHNMD) 
[45–47]. Although SM-AHNMD is classified as a single 
disease, it is now known that SM bears a mast cell, while 
AHNMD bears a myeloid component in most cases (like 
acute myeloid leukemia (SM-AML) or myeloproliferative 
neoplasm unclassifiable, chronic myelomonocytic 
leukemia (SM-CMML), primary myelofibrosis (PMF), 
atypical chronic myeloid leukemia, myelodysplastic 
syndrome/myeloproliferative neoplasm unclassificable 
(SM-MPN), myelodysplastic syndrome (SM-MDS), 
chronic eosinophilic leukemia (SM-CEL) or non-Hodgkin 
lymphoma (SM-NHL) [2, 12, 19, 46], (Table 2). In a 
clinical study comprising of 342 adult SM patients, 94% 
presented with a KIT mutation (majority bearing D816V 
mutation) out of which 40% of KIT D816V mutations 
were present in the AHNMD component [15]. In a separate 
study comprising of 48 patients with SM-AHNMD were 
analyzed for the presence of KIT mutations in the SM and 
AHNMD components of the disease; majority of KIT 
D816V mutations were found in the AHNMD component 
(89% in SM-CMML and 30% in SM-AML). Interestingly, 
in these studies, no patients with lymphoproliferative 
AHNMD displayed KIT mutations [46]. Overall, the KIT 
D816V mutation has been detected in the SM component of 
all patients, with the exception of CEL, and the frequency 
of KIT mutations in patients bearing AHNMD component 
Table 1: WHO 2008 classification of mastocytosis
Category of Mastocytosis Abbreviation Subvariants / subclasses
Cutaneous mastocytosis CM
Urticaria pigmentosa (UP)
Maculopapular CM (MPCM)
Diffuse CM
Mastocytoma of skin (MIS)
Indolent mastocytosis ISM
Smoldering SM (SSM)
Isolated bone marrow mastocytosis
Well differenciated mastocytosis
Systemic mastocytosis with associated 
non-hematological mast cell disease SM-AHNMD
SM-acute myeloid leukemia (SM-AML)
SM-myelodysplastic syndrome (SM-MDS)
SM-myeloproliferative neoplasm (SM-MPN)
SM-chronic myelomonocytic leukemia (SM-CMML)
SM-chronic eosinophilic leukemia (SM-CEL)
SM-non-Hodgkin lymphoma (SM-NHL)
SM-myeloma
Aggressive systemic mastocytosis ASM Lymphadenopathic SM with eosinophilia
Mast cell leukemia MCL Aleukemic MCL
Mast cell sarcoma MCS
Extracutaneous Mastocytoma ECM
Adapted and complied from Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris 
NL, et al editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2008. 
p. 54–63, and from Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine E, Damaj G, Dubreuil P, Arock M, 
Molecular Defects in Mastocytosis KIT and Beyond KIT, Immunol Allergy Clin N Am 2014. p. 239–262
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is significantly higher than in patients with pure-SM [46]. 
Presence of KIT D816V mutation in the disease component 
of SM-AHNMD suggests a clonal relationship between 
the two components of the disease (SM and AHNMD), 
with both appearing to have a common precursor (MC/
monocytic). One prevailing hypothesis is that KIT D816V 
is likely to be an early genetic hit in a ‘stem cell’ that gives 
rise to mast cells (the SM component) and cells of myeloid 
lineage (the AHNMD component), which likely is followed 
by a second hit in the AHNMD component, resulting in 
the development of a more aggressive form of the disease 
including SM-CMML, SM-MDS and SM-AML [2].
In MCL, the frequency of KIT D816V mutation 
is less frequent compared to ISM, with only 46% MCL 
patients expressing this mutation [48]. Interestingly, 
mutations in the ECD of KIT, juxtamembrane domain 
Table 2: Categories of mastocytosis and corresponding type of KIT mutations
Type of Mastocytosis Prognosis Treatment options Type/frequency of KIT and 
other genetic lesions
Pediatric mastocytosis (PM) Very Good Most cases regress with age
25% KIT WT
35% KIT D816V/I/Y
40% ECD KIT mutations
Indolent mastocytosis (ISM) Very good to good
No cytoreductive therapy 
necessary
> 80% KIT D816V 
mutations
Smoldering systemic 
mastocytosis (SSM)
Relatively good
‘Wait and watch’ in most cases, 
some may require Interferon 
(IFN), glucocorticosteriods and 
cladribine (2CdA)
> 80% KIT D816V 
mutations
Additional non-KIT 
mutations acquired over 
disease progression
Aggressive systemic 
mastocytosis (ASM)
Poor
IFN, 2CdA; resistant forms 
treated with TKIs/chemotherapy/
hydroxyurea
> 60% KIT D816V 
mutations
Few non-codon 816 KIT 
mutations
Additional non-KIT 
mutations
(D820G, V559I)
Systemic mastocytosis 
with associated non-
hematological MC disease 
(SM-AHNMD)
Depending on the type 
of SM and prognosis of 
associated AHNMD
Imatinib to control AHNMD; 
for SML-AML and aggressive 
types chemotherapy followed 
by allogenic stem cell 
transplantation
> 80% KIT D816V 
mutations
AHNMD presents with 
genetic lesions
Non-KIT mutations
Mast cell leukemia/Mast 
cell sarcoma (MCL/MCS)
Very poor
Polychemotherapy, allogenic 
stem cell transplantation, 2CdA, 
TKIs, Hydroxyurea
MCL: KIT D816V is least 
(46%)
KIT ECD, JMD mutations
No KIT mutation (WT 
KIT)
MCS: No KIT D816V 
mutation till date (N822K, 
del419 found)
Familial mastocytosis Usually good Imatinib and TKIs
Rare somatic KIT D816V 
mutations
Germline mutation or 
deletions (K509I, A533D, 
R634W, N821I, M835K, 
S849I or del419, del559-
560)
Adapted and compiled from Peter Valent, Mastocytosis: a paradigmatic example of a rare disease with complex biology 
and pathology, Am J Can Res 2013; 3;159–172; and from M. Arock et al, KIT mutation analysis of mast cell neoplasms: 
recommendations of the European Competence Network on Mastocytosis, Leukemia 2015, 1–10
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(JMD) or complete lack of mutations in the KIT receptor 
have also been reported in patients with MCL. Thus, 
although the overall frequency of MCL is rare, the overall 
prognosis of this disease is dismal. The last subvariant of 
mastocytosis is called MCS, which is an extremely rare 
aggressive neoplasm presenting itself as a solitary mass. 
Till date no KIT D816V mutation has been reported 
in patients with MCS, although other non-codon KIT 
mutations have been found (N822K, del419) [49] (Table 2). 
Taken together, the KIT D816V gain-of-function mutation 
is detected in almost all subtypes of mastocytosis, 
resulting in uncontrolled activation of the KIT receptor in 
the appropriate cell type of the BM. However as discussed 
earlier, the tremendous heterogeneity associated with 
various forms of mastocytosis cannot be reconciled only 
by the presence of KIT mutations, letting credence to the 
possible presence of additional genetic abnormalities in 
these patients. Below we discuss such possibilities.
Clonal evolution: additional mutations in 
conjunction with mutated KIT
Although KIT D816V mutations are present in all 
subtypes of mastocytosis, the presence of the KIT mutation 
does not always correlate with a specific sub-type of SM 
or its prognosis. Moreover, the KIT D816V mutation is 
resistant to targeted therapies such as Imatinib (Gleevec), 
and treatment with newer tyrosine kinase inhibitors (TKIs) 
like Nilotinib and Dasatinib have shown limited success 
as many patients relapse after entering remission [50, 51]. 
Although clinical trials with Midostaurin (PKC412) [41, 
52] has yielded promising results, the existing discrepancy 
of TKIs toward KIT D816V mutations in vitro (effective) 
and in vivo (not effective) suggests the possibility of yet 
unknown additional co-operating mutations that may 
contribute to the development and pathogenesis of various 
subtypes of mastocytosis and influence the response to 
TKI therapy [42, 53, 54]. One such molecular aberration 
was detected in the tumor suppressor gene TET2. In a 
clinical study involving 48 SM patients, presence of TET2 
mutation was detected in approximately 29% cases [42]. 
Specifically, TET2 mutations were identified in 15% of the 
ISM cases, 40% ASM and 35% of SM-AHNMD patients. 
Further, 50% of these patients demonstrated the presence 
of both KIT D816V and TET2 mutations, suggesting that 
the high frequency of cooperating (TET2 – KIT D816V) 
mutations may contribute to the heterogeneity observed 
in SM patients. In a separate study, prevalence of TET2 
mutations in mastocytosis patients was observed in 23% 
patients out of a total number of 26 (15 ISM, 8 SM-
AHNMD, 2 ASM, 1 MCS) [53]. Importantly, this same 
study revealed the presence of DNMT3A, ASXL1 and 
CBL mutations in 12%, 12% and 4%, respectively [53]. 
Similar to the previous study [42], in this study, 62% of 
TET2 mutations were reported in SM-AHNMD sub-group, 
while only 7% were detected in non-aggressive form of 
SM, ISM [53]. Interestingly, the SM-AHNMD sub-group 
co-expressed a combination of more than one genetic 
and/or epigenetic mutation (e.g. KIT D816V / TET2 / 
DNMT3A or TET2 / DNMT3A or TET2 / ASLXL1). Poor 
overall survival (OS) was observed in patients bearing 
TET2 mutations alone, and also in those patients in which 
more than one mutation was identified including TET2, 
DNMT3A and/or ASXL1, independent of the oncogenic 
KIT status. In yet another study involving 74 SM patients, 
82.5% patients presented with KIT mutations out of which 
78.4% showed the presence of KIT D816V mutation [55]. 
TET2 deletion was detected in 20.3% of these patients, 
and all TET2 mutations co-occurred with KIT D816V 
mutation, indicating that deregulation of epigenetic genes 
such as TET2 could promote the development of severe 
forms of SM in conjunction with KIT D816V mutations. 
A more recent study [56] highlighted the presence of 
additional mutations in a cohort of 62 patients with SM-
AHNMD including the presence of KIT mutations (87%), 
TET2 mutations (27%), ASXL1 mutations (14%) and CBL 
mutations (11%). Similar to previously reported clinical 
findings [42, 53], presence of the KIT D816V mutation 
significantly correlated with the presence of TET2 
mutations, but not with ASXL1 mutations. Although the 
percentage of TET2 mutations (27%) reported in these 
studies was higher than ASXL1 mutations (14%), only the 
presence of ASXL1 mutation remained an independent 
prognostic factor that negatively affected the OS of SM-
AHNMD patients [56]. Taken together, these studies 
suggest that cooperation between KIT and TET2 mutations 
is likely to contribute to the pathogenesis of mastocytosis; 
the possibility that ASXL1 also plays a role in this process 
cannot be ruled out. The extent to which these mutations 
function together can only be tested experimentally. 
In this regard, De Vita et al. [57] used a mouse model 
harboring TET2 deletion with concomitant KIT D814V 
expression, and demonstrated that KIT D814V and TET2 
deletion (KIT D814V, TET2-/-) cooperates in the mast cell 
compartment; resulting in a more aggressive phenotype 
as assessed by the presence of lesions in skin and the 
digestive tract [57]. More recently, Schwaab et al. [43] 
utilized next generation sequencing to investigate the 
presence of additional mutations in 39 SM patients. In 
addition to the presence of KIT D816V mutation in all 
patients tested, five additional genes were found to be 
most frequently mutated including TET2 (39%), SRSF2 
(36%), ASXL1 (20%), RUNX1 (23%) and CBL (20%). 
Importantly 10 out of 39 patients carried more than one 
TET2 mutation (two patients had four TET2 mutations), 
while one patient carried a double mutation in RUNX1, 
and two patients harbored a triple mutation in CBL.
In addition to TET2, ASXL1 appears to also be 
frequently mutated in patients with mastocytosis (12%-
20% cases) [43, 53, 56]. Traina and colleagues first reported 
ASXL1 as the only other genetic lesion that was detected in 
a patient with ISM besides KIT D816V, and also in patients 
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with SM-AHNMD. Study by Schwaab et al. concluded that 
the OS of patients with ASXL1 mutation was significantly 
shorter than patients harboring the KIT D816V mutation 
alone. Likewise, Damaj et al. showed that the presence 
of ASXL1 mutation is an independent prognostic factor 
that significantly correlates with negative OS. Overall, 
these clinical findings suggest that the presence of ASXL1 
mutations, besides KIT and TET2 may also contribute to 
the prognosis and survival of mastocytosis patients. How 
precisely these mutations contribute to disease pathogenesis 
remains an active area of investigation.
In addition to the above described mutations, 
mastocytosis patients also possess mutations in the 
Spliceosome machinery. Spliceosomes ensure the correct 
linear order of exons spliced in mRNAs, and mutations in 
these genes (SF3B1, SRSF2, and U2AF1) are frequently 
detected in patients with MDS and CMML [58]. Hanseens 
et al. [59]reported 23.6% SRSF2, 5.6% SF3B1 and 2.7% 
U2AF1 mutations in a group of 72 mastocytosis patients 
and their presence was mutually exclusive. The frequency 
of SRSF2 (23.6%) mutations in patients with mastocytosis 
appeared to be greater than TET2 mutations, at least in 
these studies [59]. Importantly, the SRSF2 mutation was 
exclusively present in the AHNMD component of all SM-
AHNMD patients examined and was specifically identified 
in the neoplastic MCs and monocytes (i.e. both in SM & 
AHNMD components). A statistical correlation between 
the presence of TET2 and SRSF2 mutations in this cohort of 
patients was also observed; however the presence of SRSF2 
mutation did not impact the OS of these patients, unlike that 
seen in patients with TET2 mutations. A few studies reported a 
slightly lower rate of mutations in genes such as CBL (3.8%-
20.5%), DNMT3A (12%), KRAS, NRAS, JAK2, EZH2 (5.1%) 
and ETV6. CBL mutations were mostly found in patients with 
SM-AHNMD, while DNMT3A and EZH2 mutations were 
primarily seen in SM patients [43, 53, 54, 56, 59].
With respect to RAS mutations (NRAS, KRAS, 
HRAS) in SM; NRAS mutation (V12) results in the 
manifestation of an ASM, MCL and/or SM like disease 
phenotype in mice. Consistently, Wilson and colleagues 
reported the presence of NRAS mutations in 4.5% SM 
patients in a cohort of 44 patients also bearing the KIT 
D816V mutation. Interestingly, 2 of these patients 
demonstrated the presence of NRAS mutation but lacked 
the KIT D816V lesion. Whether NRAS mutation precedes 
KIT mutation in the clonal development of mastocytosis 
remains to be determined [54].
While several clinical studies have shown the co-
occurence of genetic and epigenetic mutations in different 
forms of mastocytosis, a recent study showed that patients 
with advanced SM could carry as many as 3 (78% of the 
cases) and in some cases more than 5 mutations (41% of 
the cases) [43]. The combination of these mutations in these 
patients varied from the presence of a combination of KIT-
TET2-SRSF2 (26% cases) or KIT-SRSF2-RUNX1 (18% 
cases) or KIT-TET2-CBL (13% cases) or KIT-SRSF2-ASXL1 
(10% cases) or KIT-TETS2-ASXL1 (10% cases). A clinical 
follow-up was performed on 38 of 39 patients in this 
study [43]. All 6 patients who died had advanced SM 
(advSM), but more importantly 5 patients had more than 
3 mutations, while 2 patients had more than 5 mutations 
(besides KIT D816V). These findings highlight the fact 
that the severity, prognosis and overall survival of patients 
with advSM might be related to the pattern of mutations 
that are acquired during the course of the disease. It will 
be of prime importance to pursue future studies directed at 
analyzing which group of concurrent mutations (e.g. KIT-
TET2-ASXL1), and their sequential onset in the course of 
disease evolution (e.g. KIT followed by TET2 followed 
by ASXL1) plays a role in establishing the severity of 
mastocytosis and survival of patients. Gerbaulet et al. [60] 
described a mouse model where expression of KIT D814V 
mutation in immature hematopoietic cells (stem cells) and 
mature mast cells gives rise to key pathological features of 
mastocytosis observed in human patients. This model can 
be utilized to analyze the role of lesions in respective genes 
like KIT, TET2, DNMT3A, ASXL1 and CBL in the mast 
cell compartment, and analyze their relative contribution 
to the development of advSM. As currently recommended 
by the European Competence Network on Mastocytosis 
(ECNM), robust and sensitive methods like ASO-qPCR, 
RFLP, Nested RT-PCR, NGS should be incorporated to 
detect various KIT and associated mutations in neoplastic 
MCs [33]. It will be interesting to see whether the frequency 
of some of these mutations increases than current reported 
levels once these diagnostic methods are employed, and/
or yet unidentified new mutations are observed in patients 
with mastocytosis. A summary of mutations described in 
this section is depicted in Table 3.
Alternate therapeutic strategy: targeting 
downstream signaling pathways from the 
mutated KIT receptor
The mechanism of constitutive activation of the KIT 
receptor bearing the D816V mutation is at best speculative 
at present, given that the crystal structure of the kinase 
domain of KIT has not been identified. It is believed that 
the D816V mutation results in conformational changes 
in the phosphotransferase domain (PD) of KIT receptor 
relieving its auto inhibited state leading to sustained ligand 
independent activation of the KIT receptor [34]. Several 
studies have compared the downstream signaling pathways 
activated via the oncogenic KIT D816V versus the WT 
KIT receptor and have observed both qualitative as well as 
quantitative differences in their signaling potential. These 
observations provide rationale to target different signaling 
molecules that are hijacked by the mutated KIT D816V 
receptor in neoplastic MCs, thus providing alternative 
treatment strategies to treat mastocytosis, besides utilizing 
the currently available options involving TKIs, which 
show poor responses in clinical trials.
Oncotarget18256www.impactjournals.com/oncotarget
The subcellular localization of the mutated KIT 
receptor can trigger unique signals in a cell. To this end, 
the mutated KIT receptor induces oncogenic signals 
from the Golgi, and not when localized to the ER, where 
sustained activation of STAT5 but not of ERK1/2 pathway 
is observed. Similarly, cell surface localized KIT D816V 
receptor triggers sustained activation of c-CBL and SHC 
pathways, however activation of AKT and ERK1/2 requires 
the availability of SCF (in spite of D816V mutation). Thus, 
KIT can trigger differential signals based on its subcellular 
localization and/or its substrate specificity [61–63]. Here, 
we discuss various signaling pathways that play a role in the 
transformation of neoplastic MCs (Figure 1). Gleixner and 
colleagues reported the activation of SRC family kinases 
(SFKs), LYN and BTK in neoplastic MCs independent of 
the presence of KIT D816V mutation [64]. Importantly, 
Dasatinib and Bosutinib deactivated LYN/BTK and 
rescued neoplastic growth in MCs and a synergistic dose 
dependent effect on growth repression was observed when 
Dasatinib was combined with Midostaurin, highlighting 
the potential of developing new combination therapies 
to treat mastocytosis. Recently, the mTORC complex 
components (mTORC 1 & 2) have been attributed in KIT 
D816V induced neoplastic growth. mTORC1 contributes 
to MC survival, while mTORC2 plays a critical balance 
between neoplastic and dividing immature MCs leading 
to the conclusion that perhaps targeting mTORC2 would 
reduce the neoplastic MC burden, while leaving the 
normal MCs unaffected [65]. Upstream from mTORC, 
AKT also contributes to KIT D816V dependent growth 
of neoplastic MCs. Active AKT is readily detected in 
neoplastic MCs obtained from mastocytosis patients, and 
in human mastocytosis patient derived cell line HMC1.2 
active AKT regulates downstream targets like FOXO, NF-
kB, and CREB, resulting in anti-apoptotic and sustained 
cell survival signals that can contribute to malignant 
growth of neoplastic MCs [32, 66, 67]. Amongst various 
AKT inhibitors, GSK2141795 has shown some promise in 
clinical trials [68].
The role of PI3K in various other cancers, besides 
mastocytosis, is well documented and several agents 
targeting PI3K are in clinical trials [69]. Similarly, the 
role of BTK in various other malignancies like Chronic 
Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma 
(MCL) and Waldenstrom’s Macroglobulinemia (WM) 
is well established and clinical trials using Ibrutinib 
[70] has shown favorable outcomes. Given the relative 
success of PI3K [69] and BTK [70] inhibitors in treating 
other malignancies, it remains to be seen whether they 
demonstrate similar efficacy in mastocytosis patients.
In addition to a direct role for the PI3Kinase/
AKT pathway, STAT5 is also involved in the growth 
of neoplastic MCs. Knockdown of STAT5 inhibits the 
growth of neoplastic MCs. In neoplastic MCs, activated 
form of STAT5 (pSTAT5) is present in both the nuclear 
and cytosolic compartments. The presence of pSTAT5 in 
the cytosol of neoplastic MCs is due to STAT5 association/
docking with p85 subunit of PI3K via the GAB2 protein. 
This type of retention of pSTAT5 in the cytosol is 
attributed to the regulation of AKT signaling pathway 
Table 3: Mutations in KIT D816V, epigenetic regulators and other molecules detected in 
Mastocytosis
No. of 
Patients
KIT D816V 
mutations
TET2 
mutations
ASXL1 
mutations
DNMT3A 
mutations
SRSF2 
mutations
CBL 
mutations
EZH2 
mutations
RAS 
mutations
RUNX1 
mutations
JAK 
mutations
Reference
n = 48 20% 29% N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Tefferi 
et al.42
n = 26 38.4% 23% 12% 11.5% N.D. 3.8% 0% N.D. N.D. N.D. Traina 
et al.53
n = 74 78.4% 20.3% N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. Soucie 
et al.55
n = 62 87% 27% 14% N.D. N.D. 11% N.D. N.D. N.D. 13% Damaj 
et al.56
n = 39 100% 39% 20% N.D. 35.8% 20% 5.1% 15.3% 23% 5.1% Schwaab 
et al.43
n = 72 81% 21% N.D. 12% 23.6% N.D. N.D. N.D. N.D. N.D. Hanssens 
et al.59
n = 44 100% N.D. N.D. N.D. N.D. N.D. N.D. 4.5% N.D. N.D. Wilson 
et al.54
Less frequent Mutations in U2AF1 (5.1%), ETV6 (2.5%), SETBP1 (2.5%) have been reported by Schwaab et. al; and 
mutations in SF3BP1 (5.6%) and U2AF1 (2.7%) have been reported by Hanssens et.al. Mutations in IDH1, IDH2 have 
not been detected in studies reported thus far. RAS mutations denote total mutations identified in both KRAS and NRAS. 
N.D. signifies “Not Determined”. NOTE: Mutations represented above includes total (%) of those present alone (ex. KIT 
D816V), and with other mutations (ex. KIT D816V + TET2).
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in neoplastic MCs. Thus STAT5 function in neoplastic 
MCs is linked to the PI3K/AKT signaling pathways. 
Although these studies [66, 71, 72] indicate STAT5 as 
a bonafide target for treating mastocytosis, designing 
STAT5 inhibitors that can be used to treat different 
forms of mastocytosis still remains a challenge and an 
actively studied area of research. Chaix and colleagues 
[73] reported a role of JAK in phosphorylation of STAT 
proteins downstream of KIT D816V mutant bearing cells, 
and mutations in JAKs (5.1%–13%) [43, 56] have been 
identified in mastocytosis patients. Together these data 
indicate that JAKs can also be potential targets to treat 
mastocytosis. On the other hand, JAK mutations have also 
been found in CML, and a first generation JAK inhibitor 
Roxolitinib has been approved to treat myelofibrosis. 
Second generation JAK inhibitors like Lestaurtinib (CEP-
701), and Pacritinib (SB1518) have shown promising 
results in clinical trials [74]. It remains to be seen whether 
these inhibitors can also be used for treating patients with 
mastocytosis.
SHP2 phosphatase is hyperactive and overexpressed 
in cells bearing the KIT D816V mutation [75]. Using a 
salicyclic acid based inhibitor II-BO8, which has enhanced 
selectivity and affinity for SHP2, its activity downstream 
of KIT D816V can be inhibited, which results in the 
repression of constitutive growth and survival of these 
cells. In these cells, constitutively active SHP2 recruits 
PI3K and GAB2 that leads to the activation of AKT/ERK 
pathways resulting in KIT D814V mediated transformation. 
More importantly, treatment of mice transplanted with KIT 
D814V bearing cells with a combination of II-BO8 and 
PI3K inhibitor LY294002 shows enhanced survival, than 
treatment with II-BO8 or LY294002 alone. In another study, 
downstream of activated KIT D814V receptor, a PI3Kinase/
RHOA mediated activation of ROCK1 was shown to 
induce transformation and myeloproliferative neoplasm 
Figure 1: Targeting various downstream signaling pathways from mutated KIT D816V receptors are depicted. PI3K 
mediated activation of RAS-MAPK-JNK pathway, AKT-ERK and ATK-mTORC2 pathway leads to survival of neoplastic MCs. Recent 
studies highlight newer pathways mediated by SHP2, FAK, ROCK are described with corresponding inhibitors that hold promise. (1) SHP2 
and P13K/GAB2 induced AKT/ERK activation can be inhibited using SHP2 specific inhibitor IIBO8, (2) FAK/TIAM1/RAC1/PAK1 
mediated nuclear translocation of active STAT5 in SM patients can be inhibited by targeting FAK and PAK1 (4) with inhibitors, (3) PI3K 
mediated activation of RAC1 via VAV1 can be targeted using novel RAC1 inhibitor Ehop-016, (5) PI3K/RHOA mediated activation 
of ROCK1 can be targeted by inhibitor H-1152 against ROCK1, (6) targeting PI3K using inhibitors that have shown promise in other 
malignancies [69], (7) targeting AKT (GSK2141795), (8) inhibiting JAK with Roxolitinib, Lestaurtinib , Pacritinib, and (9) targeting 
epigenetic regulators ASXL1, DNMT3A and TET2 by 5-azacytidine (5′-AZA) and 5-aza-2′ deoxycytidine (Decitabine/DAC).
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in mice [76]. Genetic ablation of ROCK1 or targeting it 
with a pharmacological inhibitor, H-1152, results in the 
inhibition of myeloproliferative neoplasm and prolongs the 
survival of these mice.
More recently, Martin et al. [77] demonstrated a 
VAV1/RAC1/PAK signaling pathway downstream of KIT 
D814V mutated receptor in triggering myeloproliferative 
neoplasm in mice. These studies showed that targeting RAC 
GTPases with a novel small molecule inhibitor Ehop-016 
results in a significant repression of disease progression 
in mice. Mechanistically, treating KIT D814V cells with 
Ehop-016 results in enhanced cell death via repression of an 
anti-apoptotic protein BAD. Along similar lines, Chatterjee 
et al. [78] demonstrate a novel signaling pathway comprised 
of FAK/TIAM1/RAC1/PAK1 in regulating the nuclear 
translocation of active STAT5 with subsequent expression of 
pro-survival genes resulting in MPN in mice, downstream of 
oncogenic KIT D814V. Genetic ablation or pharmacological 
inhibition of FAK or PAK1 resulted in repression of KIT 
D814V induced MPN development in mice. Moreover 
in these studies [77, 78], the authors also showed growth 
repression of neoplastic MCs derived from SM patients that 
were positive for KIT D816V mutation, when treated with 
FAK and PAK1 inhibitors, indicating an essential role of 
FAK and PAK1 in triggering KIT D816V induced SM.
In addition to a role for kinases and phosphatases 
in regulating KIT D816V induced transformation, a 
relationship between KIT D816V induced SM and 
transcription factors like STAT5 and MITF is also evident 
from recent studies. Hoermann et al. [79] demonstrated 
that in KIT D816V bearing neoplastic mast cells, active 
STAT5 induces expression of Oncostatin M (OSM), a key 
modulator of bone marrow microenvironment. Increased 
OSM expression causes increased angiogenesis, thickened 
trabeculae and fibrosis; all pathological hallmarks of SM. 
This study highlighted STAT5 and OSM as potential 
targets to treat SM [79]. Like STAT5, another transcription 
factor called microphthalmia-associated transcription 
factor (MITF) is highly expressed in neoplastic cells 
derived from bone marrow of SM patients harboring the 
KIT D816V mutation [80]. At the microRNA (miRNA) 
level, activating KIT D816V mutation represses the 
expression of miR-539 and miR-381, which is normally 
involved in down-regulating MITF in mast cells, 
demonstrating that KIT D816V promotes the stability of 
MITF which plays an essential role in proliferative effects 
seen in mastocytosis. Although the above described 
signaling pathways are exciting; they will however require, 
further stringent analysis to determine whether genetic 
lesions/mutations/sustained activation occur per se in 
RAC1/PAK1/FAK/SHP2 molecules in neoplastic MCs 
found in mastocytosis patients. Furthermore, a mouse 
model developed by Gerbaulet et al. [60] that shows 
many cardinal features of human mastocytosis due to 
the presence of the activating KIT D814V mutation and 
can be induced to express in multiple hematopoietic stem 
and progenitor cell lineages (stem cells vs. mast cells), 
can be further utilized to determine the role of various 
signaling molecules described above by targeting them 
using pharmacological inhibitors or genetic ablation, 
and analyzing their contribution to the development of 
mastocytosis. These studies will be important to validate 
SHP2/RAC1/PAK1/FAK as genuine therapeutic targets 
for treating mastocytosis, along with clinical trials using 
inhibitors against these molecules.
Current treatment options and challenges
The majority of patients diagnosed with 
mastocytosis belong to the indolent category (ISM), a 
form compatible with an individual’s life span. In patients 
suffering from ISM, a minimum treatment however is 
necessary, which includes management of symptoms, 
anti-mediator drugs and careful monitoring of the disease. 
In contrast, in patients diagnosed with an advanced/
aggressive form of SM, which is incurable, and results 
in a shortened life expectancy; treatment with TKIs has 
yielded disappointing results. In general, the type of 
mutation in the KIT receptor determines the efficacy of 
some of the known TKIs. Patients with KIT mutations 
in the second catalytic domain (D816V/H/Y/N) tend 
to demonstrate resistance to Imatinib [81]. This is due 
to disruption of the conformation of the KIT D816V 
mutant receptor, rendering the receptor permanently 
active, which cannot be targeted by Imatinib. On the 
other hand, treatment with Imatinib has yielded dramatic 
improvement in MC burden and clinical symptoms 
in patients with a history of CM harboring a germline 
mutation in the KIT receptor (F522C). Most mutations 
found in ECD of the KIT receptor, primarily those 
detected in pediatric patients, respond well to Imatinib 
[82, 83]. Likewise, Imatinib treatment of a MCL patient 
with an ECD KIT mutation (A502-Y503dup) and of 
patients with no mutations in the KIT receptor (i.e. WT 
KIT) showed favorable outcomes [84]. Further, several 
other TKIs have been developed in recent years that can 
efficiently target the KIT D816V lesion. Dasatinib is 
potent against cell lines harboring KIT D816V mutations, 
unfortunately clinical trials yielded disappointing results 
[51, 64, 85]. Midostaurin (PKC412) is a potent inhibitor 
of PKC, VEGFR-2, PDGFR, FLT3 and KIT. It inhibits 
the activity of KIT in HMC mastocytosis cell line, and 
at pharmacological relevant concentrations against patient 
derived neoplastic MCs in vitro. Consistent with the 
in vitro observations, in several clinical trials, a significant 
reduction in MC burden in patients with ASM and MCL 
is observed using Midostaurin [41, 86]. Although initial 
data from these clinical trials were encouraging, they 
did not offer long-term remission. Besides TKIs, current 
non-targeted cytoreductive therapy using Cladribine and 
Interferon-α have also has shown encouraging results in 
more aggressive forms of the disease (Table 2).
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Another aspect of KIT D816V resistance to current 
therapies involves the presence of several KIT D816V-
independent signaling pathways that are likely to contribute 
to the survival and abnormal growth of neoplastic MCs [64]. 
These KIT D816V-independent pathways may support the 
presence of malignant subclone(s), which may contribute to 
relapse in patients treated with TKIs who bear KIT D816V 
negative neoplastic MCs. Thus, therapeutic targeting of 
additional signaling pathways and molecules may also be a 
prudent therapeutic approach to treat advanced/aggressive 
forms of this disease.
One of the major means by which neoplastic 
mast cells harboring the mutated KIT D816V receptors 
achieve enhanced survival is through down-regulating 
the expression of pro-apoptotic and up-regulation of anti-
apoptotic proteins. The mutated KIT D816V receptor 
phosphorylates the pro-apoptotic protein BIM which 
results in its degradation leading to enhanced survival. 
The proteasomal inhibitor MG132 up-regulates the 
expression of BIM and subsequently induces apoptosis 
in KIT D816V harboring cells, providing a strong 
rationale for using proteasomal inhibitors as a treatment 
option for mastocytosis. Obatoclax, an inhibitor of anti-
apoptotic family of proteins (BCLXL, BCL2 and MCL1) 
shows reduced growth and survival in cells expressing 
KIT D816V mutation. Further, Obatoclax synergizes 
and potentiates the activity of antineoplastic drugs such 
as Dasatinib, Midostaurin and Bortezomib, highlighting 
the importance of combination therapy for SM. Martin 
et al. [77] showed increased apoptosis in KIT D814V 
bearing cells with a novel RAC1 inhibitor Ehop-016 
in part by repressing the expression of anti-apoptotic 
proteins BAD and MLC, while Chatterjee et al. [78] 
showed that pharmacological targeting of FAK and 
PAK1 in KIT D816V cells results in down-regulation 
of anti-apoptotic protein and mRNA levels of BCLXL. 
A number of FAK inhibitors are currently in clinical 
trials; whether future clinical studies incorporating FAK, 
RAC1 and PAK1 inhibitors alone, or in combination 
with other antineoplastic agents like Dasatinib and 
Midostaurin provide a better treatment option for ASM 
patients remains to be seen. Targeting PAK proteins as 
a therapeutic strategy is currently been tried for various 
malignancies; as more small molecule inhibitors with 
increased specificity become available, they are likely 
to be tested in SM patients. In addition to regulating 
apoptosis, genetic ablation of PAK1 enhanced the survival 
of KIT D814V bearing mice in secondary transplants, 
indicating that targeting PAK1 inhibits the growth/
survival of KIT D814V bearing leukemia initiating cell 
(LIC) [78]. It will be interesting to elucidate the LIC 
containing fraction in the HSC pool that triggers KIT 
D814V induced mastocytosis, which subsequently can be 
targeted using PAK1 inhibitors. This will be an important 
area of future research, as the LIC population is known 
to survive conventional therapy, and the survival of LICs 
has been implicated in the observed relapse often seen in 
SM patients. Besides molecules described above, clinical 
trials against BTK, PI3K and JAK have already shown 
promising results in various other malignancies (discussed 
earlier under “Alternate Therapeutic Strategy”). Thus 
targeting BTK, PI3K, JNK in clinical trials involving 
mastocytosis patients holds significant promise.
In addition to targeting the KIT D816V receptor and 
its downstream substrates in SM, HMC cells and primary 
neoplastic mast cells derived from aggressive SM patients 
carrying the KIT D816V mutation appear to be sensitive to 
treatment by demethylating agents including 5-azacytidine 
(5-AZA) and 5-aza-2′deoxycytidine (Decitabine / DAC). 
5-AZA and DAC do not alter the expression of KIT 
receptor, nor do they impact the activation of downstream 
signaling proteins like AKT, STAT5 or STAT3; rather they 
induce apoptosis by re-expression of FAS (Fas cell surface 
death receptor) [87]. Importantly, 5-AZA and DAC do 
not show any appreciable toxicity toward normal bone 
marrow or mast cells. Along these lines, a combinatorial 
approach involving Dasatinib (DASA) and DAC in 
treating cells derived from SM patients that harbor the 
KIT D816V and TET2 deletion was described [57]. Since 
loss of TET2 causes aberrant methylation of promoter 
regions in AML [88], a similar effect in SM patients was 
predicted. To investigate this hypothesis, the authors 
knocked down TET2 in HMC1.2 cells harboring the KIT 
D816V mutation, and pre-treated cells with low doses of 
DAC followed by DASA and determined cell death. Loss 
of TET2 sensitized SM cells to a combination of drugs 
(DAC+DASA), leading to significantly higher apoptosis, 
than in cells treated with each drug alone [57]. This 
approach paves the way for future treatment strategies 
for KIT D816V positive and TET2 mutation carrying 
SM patients, where pre-treatment with demethylating 
agents like DAC followed by TKIs like Dasatinib and 
Midostaurin may yield better therapeutic outcomes. In 
addition to the above described strategy of using drug 
combinations, a synergistic inhibitory effect exerted by 
a combination treatment of Ponatinib and Midostaurin or 
Dasatinib on the growth of neoplastic mast cells has also 
been described [52]. Whether results from combination 
treatments in vitro translate into successful clinical studies 
remains to be seen, as it will take considerable effort to 
elucidate the sequential order of drugs, and concentrations 
that do not confer toxicity. Further, it might be valuable 
to consider a three-pronged therapeutic approach for 
the treatment of SM patients harboring the KIT D816V 
mutation. In this scenario, co-targeting downstream 
effector molecules such as SHP2, FAK, RAC1, and PAK1 
along with the KIT D816V receptor itself using TKIs, and 
epigenetic regulators with demethylating agents might 
result in better outcomes (Figure 1).
The challenges posed by the mutated KIT D816V 
receptor has resulted in the development of newer strategies 
for designing potent inhibitors by exploiting the unique 
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structural conformation KIT receptor adopts in its active 
versus its inactive state. Bai et al. [89] utilized a rational 
drug design to target the ‘switch pocket’ (SP) region of 
KIT that is occupied by different switch regions giving the 
receptor either an ‘active’ or ‘inactive’ conformation. The 
drugs DP-2976 and DP-4851 exhibit potent anti-neoplastic 
activity against HMC and bone marrow mast cells derived 
from SM patients [89]. These drugs hold significant promise 
since mechanistically they function differently from current 
drugs like Imatinib and Midostaurin, which are ATP 
competitors, while DP-2976 and DP-4851 are non-ATP 
competitors. Lee at al. [90] have reported the development 
of a new series of 7-azaindole based inhibitors that show 
a 100-fold increased sensitivity toward the KIT D816V 
mutation than wild-type KIT receptor. It will be interesting 
to see results using these drugs in future clinical trials.
Concluding remarks and future perspectives
In mastocytosis, both in the indolent (ISM) and in 
the aggressive (ASM) form of the disease, mutations in 
the KIT receptor (D816V and others) and genetic lesions 
in various signaling molecules and modifiers are observed. 
To treat the aggressive form of the disease, targeting 
the activated version of the mutated KIT receptor with 
drugs has been largely ineffective, therefore co-targeting 
selective molecules in signaling pathways downstream of 
the mutated KIT receptor is likely to be prudent therapeutic 
strategy. Moreover, application of combination therapies 
during the initial phase of disease may optimize the 
clearance of neoplastic MC burden that may in-turn reduce 
drug-resistance induced relapse. However, to efficiently 
eradicate neoplastic MCs, targeting tumor stem/leukemia 
initiating cells (LIC) is also necessary. Importantly, the 
detection and quantification of KIT allele burden will be 
critical for monitoring the disease, its prognosis during the 
course of the disease and during/after therapies. Fortunately, 
highly specific PCR-based assays are readily available that 
should be incorporated as a standard routine in screening 
mastocytosis patients with KIT mutations. Moreover, to 
expand the breadth of screening for mutations in newly 
described players in this disease such as TET2, ASXL1 and 
SRSF2; methods such as next-generation sequencing (NGS) 
and evaluation of myeloid-gene mutation panel are likely to 
be of benefit [33]. These approaches will hopefully provide 
the tools to diagnose and treat the mutational patterns, 
course and aggressiveness of the disease and alleviate the 
suffering in mastocytosis patients.
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